NBIX · Neurocrine Biosciences Inc
$180.79
-2.04 (-1.12%)
At close · Jul 29
Earnings today
Market Cap
$18.18B
Shares
100.55M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-05-28 | 2026-05-27 | |
| 8-K | 2026-05-18 | 2026-05-14 | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| 8-K | 2026-05-05 | — | |
| DEF 14A | 2026-04-15 | — | |
| 8-K | 2026-04-06 | 2026-04-05 | |
| 8-K | 2026-02-11 | — | |
| 10-K | 2026-02-11 | 2025-12-31 | |
| 8-K | 2025-11-24 | 2025-11-21 | |
| 10-Q | 2025-10-28 | 2025-09-30 | |
| 8-K | 2025-10-28 | — | |
| 8-K | 2025-07-30 | — | |
| 10-Q | 2025-07-30 | 2025-06-30 | |
| 8-K | 2025-05-30 | — | |
| 8-K | 2025-05-22 | 2025-05-21 | |
| 10-Q | 2025-05-05 | 2025-03-31 | |
| 8-K | 2025-05-05 | — | |
| DEF 14A | 2025-04-09 | — | |
| 8-K | 2025-04-04 | 2025-04-02 | |
| 10-K | 2025-02-10 | 2024-12-31 | |
| 8-K | 2025-02-06 | — | |
| 8-K | 2025-01-27 | 2025-01-24 | |
| 8-K | 2024-12-20 | — | |
| 8-K | 2024-11-01 | 2024-10-31 | |
| 10-Q | 2024-10-30 | 2024-09-30 | |
| 8-K | 2024-10-30 | — | |
| 8-K | 2024-10-11 | — | |
| 8-K | 2024-08-28 | — | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-08-01 | — | |
| 8-K | 2024-05-28 | 2024-05-24 | |
| 8-K | 2024-05-23 | 2024-05-22 | |
| 8-K | 2024-05-01 | — | |
| 10-Q | 2024-05-01 | 2024-03-31 | |
| DEF 14A | 2024-04-10 | 2024-05-22 | |
| 10-K | 2024-02-09 | 2023-12-31 | |
| 8-K | 2024-02-07 | — | |
| 8-K | 2023-11-13 | 2023-11-10 | |
| 8-K | 2023-11-09 | — | |
| 8-K | 2023-10-31 | — | |
| 10-Q | 2023-10-31 | 2023-09-30 | |
| 8-K | 2023-10-06 | 2023-10-05 | |
| 8-K | 2023-10-05 | — | |
| 8-K | 2023-09-12 | — | |
| 8-K | 2023-08-01 | — | |
| 10-Q | 2023-08-01 | 2023-06-30 | |
| 8-K | 2023-07-13 | 2023-07-10 | |
| 8-K | 2023-07-12 | 2023-07-11 |
Showing 1–50 of 109 filings
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
255 filings
228 filers
Visit website
Investor relations